Skip to main content
Back to jobs

Associate Director, Quality Control Technical Services

External
beamtherapeutics logoBeamtherapeutics · Cambridge, MA
Full-timeOn-site1mo ago30+ days old, may be filled
DocumentationLeadership
Cover LetterConnect

Prepare for this interview

Elite

AI-generated questions, company research, and talking points tailored to this role


Benefits

Vision insurance

Additional Information

Company Overview: Beam Therapeutics is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform with integrated gene editing, delivery and internal manufacturing capabilities. Beam's suite of gene editing technologies is anchored by base editing, a proprietary technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This has the potential to enable a wide range of therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases. Position Overview: We are seeking an Associate Director, Quality Control Technical Services to lead QC CMC strategy for our ex vivo cell therapy franchise, spanning late-stage development, initial commercial launch, and ongoing lifecycle management. This role will also play a critical leadership role in defining and executing the strategy for mRNA drug substance and critical materials platforming, supporting both current programs and future pipeline scalability. The successful candidate will work cross‑functionally with Analytical Research & Development, Bioprocess Development, Manufacturing Technical Services, Manufacturing Operations, Regulatory Affairs, and Quality Assurance to drive the transfer, qualification, validation, and lifecycle management of analytical methods for gene‑edited cell therapy products and associated critical materials (e.g., mRNA). These efforts will ensure analytical readiness to support regulatory submissions, agency approvals, and commercial supply. This role will be instrumental in defining the QC testing and technical transfer strategy for next‑generation autologous cell therapy manufacturing, including the transfer of automated and validated analytical methods to Beam's internal manufacturing facility. A key focus will be the internalization of validated mRNA methods into the North Carolina Quality Control laboratory, strengthening in‑house testing capabilities and long‑term operational resilience. In addition, this position will contribute directly to regulatory filings, including specifications, analytical method validation reports, and CMC documentation, and will serve as a QC technical subject matter expert across program teams to ensure compliant, robust, and phase‑appropriate analytical strategies. Primary Responsibilities: Lead and influence QC CMC strategy in partnership with cross‑functional CMC teams for master cell banks (MCBs), plasmids, and mRNA drug substance and critical materials, supporting both ex vivo and in vivo therapy programs across development and commercialization. Define and execute the QC testing, method strategy, and technical execution to enable next‑generation autologous cell therapy manufacturing processes, including analytical readiness for process validation, comparability, and technology transfer. Own and coordinate analytical method transfer, qualification, and validation activities across internal and external QC laboratories, ensuring compliant, phase‑appropriate, and inspection‑ready execution. Establish and maintain analytical control strategies by tracking and trending in‑process, release, and stability data, collaborating with statisticians and program teams to define and justify specifications for MCBs, plasmids, mRNA, and autologous cell therapy products. Define and oversee stability strategies and programs for MCBs, plasmids, mRNA, and ex vivo cell therapy products, ensuring alignment with regulatory expectations and lifecycle needs. Lead analytical method lifecycle management for late‑stage and commercial ex vivo portfolio, including method performance monitoring, remediation, comparability activities, and continuous improvement. Drive the internalization of validated mRNA analytical methods into Beam's North Carolina Quality Control laboratory, strengthening internal capabilities and supporting long‑term commercial supply. Author and review Quality System documentation, including SOPs, Change Controls, and CAPAs, to support method implementation, lifecycle changes, and inspection readiness. Partner with Regulatory Affairs-CMC to author, review, and coordinate CMC sections of regulatory submissions, including specifications, method validation reports, and responses to agency queries. Ensure QC visibility and alignment on regulatory interactions, including tracking agency questions, commitments, post‑approval requirements, and method introduction or change strategies. Serve as a key QC technical interface across CMC, Quality, Regulatory, Manufacturing, Process Development, Analytical Research & Development, and external partners, providing clear


Your Match

How well this role fits your profile.

Company Intel

What employees say

Worked at beamtherapeutics? Share your experience

Interested in this role?

Apply on the company's website.

Cover LetterConnect